摘要
目的探讨RNA特异性腺苷脱氨酶1(adenosine deaminase acting on RNA-1,ADAR1)在肺腺癌组织中的表达及其与患者临床病理特征和预后的相关性。方法通过免疫组织化学染色法检测2015年12月至2017年9月本院收治的131例肺腺癌患者术后组织标本以及相应癌旁组织中ADAR1的表达,分析ADAR1蛋白的表达与患者临床病理参数的关系,并利用Kaplan-Meier法分析ADAR1表达水平和患者总生存期(overall survival,OS)的关系,拟合Cox模型评价不同指标的预后价值。结果肺腺癌组织中ADAR1蛋白表达量为77.9%,显著高于相应配对的癌旁组织(12.5%,P<0.01),且ADAR1表达与患者临床分期和淋巴结转移有关(P<0.05),Kaplan-Meier分析表明ADAR1高表达与较短的OS显著相关(HR=2.671,95%CI:1.282~5.563,P<0.01);多因素Cox回归分析显示,临床分期和淋巴结转移(P<0.01)可作为肺腺癌患者预后评估的独立危险因素。结论 ADAR1在肺腺癌组织中高表达,且肺腺癌患者中ADAR1高表达提示预后不良。
Objective To investigate the expression of adenosine deaminase acting on RNA-1(ADAR1) in lung adenocarcinoma and its association with clinicopathological characteristics and prognosis.Methods Immunohistochemical staining was applied to detect the expression of ADAR1 in the tumor tissues and corresponding adjacent normal tissues of 131 patients with lung adenocarcinoma treated in our hospital from December 2015 to September 2017.The association between the expression of ADAR1 protein and clinicopathological parameters was analyzed.Kaplan-Meier analysis was performed to analyze the correlation between ADAR1 level and patients’ overall survival(OS),and fitting Cox model was used to evaluate the prognostic values of different indixes.Results ADAR1 was highly expressed in 102 cases(77.9%) of the patients,while only 21 cases(12.5%) of paired para-carcinoma tissues,indicating a significant difference(P<0.001),and the level of ADAR1 was correlated with clinical stage and lymph node metastasis(P<0.05).Kaplan-Meier analysis showed that higher expression of ADAR1 was remarkably associated with shorter OS(HR=2.671,95%CI:1.282~5.563,P<0.01).Multivariate Cox regression analysis suggested that clinical stage and lymph node metastasis(P<0.01) were independent risk factors for prognosis of the patients.Conclusion ADAR1 is highly expressed in lung adenocarcinoma tissues,and the patients with higher expression indicate poorer prognosis.
作者
杨文娣
余钱
郭政军
张晓月
彭媛
杨镇洲
YANG Wendi;YU Qian;GUO Zhengjun;ZHANG Xiaoyue;PENG Yuan;YANG Zhenzhou(Cancer Center,the Second Affiliated Hospital of Chongqing Medical University,Chongqing,400010,China)
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2021年第24期2683-2687,共5页
Journal of Third Military Medical University
基金
重庆医科大学附属第二医院“宽仁英才”项目(202007)
重庆市自然科学基金博士后科学基金(cstc2019jcyj-bshX0056)。
关键词
RNA特异性腺苷脱氨酶1
肺腺癌
临床分期
预后
adenosine deaminase acting on RNA-1
lung adenocarcinoma
clinical stages
prognosis